| Titre : | Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. (1998) |
| Auteurs : | M. KRAHN ; A.S. DETSKY ; R. GUASPARINI ; M. SHERMAN |
| Type de document : | Article |
| Dans : | American journal of public health (vol. 88, n° 11, 1998) |
| Pagination : | 1638-1644 |
| Langues: | Anglais |
| Mots-clés : | Hépatite virale B ; Virose ; Infection ; Prévention santé ; Vaccination ; Programme élargi vaccination ; Programme santé ; Analyse coût efficacité ; Economie santé ; Enfant ; Homme ; Enfant 6 9 ans ; Appareil digestif [pathologie] ; Foie [pathologie] |
| Résumé : | [BDSP. Notice produite par INIST R0xm3Nos. Diffusion soumise à autorisation]. Objectives. This study evaluated the costs and cost-effectiveness of a shcool-based grade 6 universal vaccination program against hepatitis B. Methods. We performed a descriptive cost study and cost-effectiveness analysis of British Columbia's vaccination program for 1994 and 1995. Since 1992, public health nurses have administered hepatitis B vaccine to grade 6 students in shcools. We measured costs of vaccine, vaccine administration, and net program costs and used a validated Markov model to calculate the cost-effectiveness of the program. Results. Vaccinating each student cost $44, $24 of which was the cost of vaccine administration. The net cost was $9 per person ; considering productivity costs, net savings were $75 per person. Marginal cost per life year gained was $2100. Universal adolescent vaccination is also economically attractive in regions with incidence rates below 3 cases per 100 00 per year. Conclusions. Hepatitis B vaccine can be delivered in North American schools at a reasonable cost. Adolscent veccination is economically attractive in North American regions of high and average incidence rates. Our analysis supports vaccination in adolescents who remain at risk for hepatitis B virus infection. |

